Free Trial
NASDAQ:ORGS

Orgenesis 5/21/2024 Earnings Report

Orgenesis logo
$1.32 -0.09 (-6.17%)
As of 07/9/2025 03:52 PM Eastern

Orgenesis EPS Results

Actual EPS
-$2.90
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Orgenesis Revenue Results

Actual Revenue
$0.14 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Orgenesis Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Orgenesis' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules.

Conference Call Resources

Orgenesis Earnings Headlines

Orgenesis (NASDAQ:ORGS) Trading Down 6.6% - What's Next?
Orgenesis Delays Filing of Quarterly Report
How a Kansas farm boy gained 1,285% in two days
A former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a meme stock. It was a pattern called “Crossfire” — a 3-step setup you can execute in a normal brokerage app. Master trader Jeff Clark is now revealing how it works in a free 30-minute video, available for a limited time.
Orgenesis secures $5M equity investment from Williamsburg Venture
See More Orgenesis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orgenesis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orgenesis and other key companies, straight to your email.

About Orgenesis

Orgenesis (NASDAQ:ORGS), a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

View Orgenesis Profile

More Earnings Resources from MarketBeat